C74 ADVANCES IN TRANSLATIONAL COPD: Chf-6297, A Novel Selective P38α (mapk14) Inhibitor Designed For Inhalation Delivery, Effectively Counteracts Il-1β-Evoked Acute Lung Inflammation

By utilizing a rat model of acute lung injury, we demonstrated that inflammatory response induced by IL-1ß instillation is accompanied by upregulation of p38a signaling and is counteracted by intratracheal administration of the novel potent and selective p38a inhibitor, CHF-6297 (CHI-91040). Intratr...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 195
Main Authors Facchinetti, F, Martucci, A, Moretto, N, Aquino, G, Puccini, P, Murgo, A, Capaldi, C, Armani, E, Fitzgerald, M, Finch, H, Fox, C, Patacchini, R, Villetti, G, Civelli, M
Format Journal Article
LanguageEnglish
Published New York American Thoracic Society 01.01.2017
Subjects
Chronic obstructive pulmonary disease
Inflammation
Neutrophils
Rodents
Online AccessGet full text

Cover

More Information
Summary:By utilizing a rat model of acute lung injury, we demonstrated that inflammatory response induced by IL-1ß instillation is accompanied by upregulation of p38a signaling and is counteracted by intratracheal administration of the novel potent and selective p38a inhibitor, CHF-6297 (CHI-91040). Intratracheal recombinant rat IL-1ß dose dependently increased neutrophil numbers and IL-6 levels in bronchoalveolar lavage (BAL), a phenomenon accompanied by p38 MAPK signaling activation as detected by phosphorylation of HSP27 in lung homogenates.
ISSN:1073-449X
1535-4970